Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel

J. Caers, B. Paiva, E. Zamagni, X. Leleu, J. Bladé, S. Y. Kristinsson, C. Touzeau, N. Abildgaard, E. Terpos, R. Heusschen, E. Ocio, M. Delforge, O. Sezer, M. Beksac, H. Ludwig, G. Merlini, P. Moreau, S. Zweegman, M. Engelhardt, L. Rosiñol

Research output: Contribution to journalReview articleAcademicpeer-review

149 Citations (Scopus)


Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography-computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.
Original languageEnglish
Article number10
JournalJournal of Hematology and Oncology
Issue number1
Publication statusPublished - 2018

Cite this